- Home
- NVX vs DRUG Comparison
NVX vs DRUG Comparison
Compare NVX & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVX
- DRUG
- Stock Information
- Founded
- NVX 2012
- DRUG 2019
- Country
- NVX Australia
- DRUG United States
- Employees
- NVX N/A
- DRUG N/A
- Industry
- NVX Industrial Machinery/Components
- DRUG Pharmaceuticals and Biotechnology
- Sector
- NVX Miscellaneous
- DRUG Health Care
- Exchange
- NVX Nasdaq
- DRUG Nasdaq
- Market Cap
- NVX 176.8M
- DRUG 199.7M
- IPO Year
- NVX N/A
- DRUG N/A
- Fundamental
- Price
- NVX $1.17
- DRUG $33.63
- Analyst Decision
- NVX
- DRUG Strong Buy
- Analyst Count
- NVX 0
- DRUG 7
- Target Price
- NVX N/A
- DRUG $83.25
- AVG Volume (30 Days)
- NVX 389.6K
- DRUG 37.4K
- Earning Date
- NVX 01-01-0001
- DRUG 08-13-2025
- Dividend Yield
- NVX N/A
- DRUG N/A
- EPS Growth
- NVX N/A
- DRUG N/A
- EPS
- NVX N/A
- DRUG N/A
- Revenue
- NVX $5,854,424.00
- DRUG N/A
- Revenue This Year
- NVX $135.22
- DRUG N/A
- Revenue Next Year
- NVX $1,647.66
- DRUG N/A
- P/E Ratio
- NVX N/A
- DRUG N/A
- Revenue Growth
- NVX N/A
- DRUG N/A
- 52 Week Low
- NVX $0.81
- DRUG $0.94
- 52 Week High
- NVX $2.73
- DRUG $79.02
- Technical
- Relative Strength Index (RSI)
- NVX 42.46
- DRUG 64.40
- Support Level
- NVX $1.51
- DRUG $31.80
- Resistance Level
- NVX $2.04
- DRUG $36.50
- Average True Range (ATR)
- NVX 0.19
- DRUG 2.44
- MACD
- NVX -0.04
- DRUG 0.79
- Stochastic Oscillator
- NVX 6.45
- DRUG 70.86
About NVX NOVONIX Limited American Depository Shares
NOVONIX Ltd operates in the lithium-ion battery industry. The company has three operating segments namely Graphite Exploration, Battery Technology, and Battery Materials. Graphite Exploration segment is engaged in the exploration and development of high-grade flake graphite deposits. The Battery Technology segment develops battery cell testing equipment and carries out research and development in battery development. The Battery Materials segment develops and manufactures battery anode materials. The Battery Technology segment generates maximum revenue for the company.
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.